GSK licenses BioWa antibody potency technology
This article was originally published in Scrip
BioWa has non-exclusively licensed rights to its Potelligent antibody potency-enhancing technology toGlaxoSmithKline, which will apply it to multiple, selected development-stage antibodies. The technology enhances antibody-dependent cellular cytotoxicity by reducing the amount of antibody fucose, using a fucosyl transferase gene knockout cell production system. BioWa, a wholly owned US subsidiary of Japan's Kyowa Hakko Kirin, will receive undisclosed up front, milestone and sales royalty payments as part of the agreement.